Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.51 |
| ▸ | STRADA | Q7RTN6 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3523523 | 0.94 | MAPK14 (0.53) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3520717 | 0.91 | MAPK14 (0.57) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3521117 | 0.90 | MAPK14 (0.65) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3524504 | 0.90 | MAPK14 (0.64) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3519366 | 0.90 | MAPK14 (0.63) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3523573 | 0.90 | MAPK14 (0.56) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL3525427 | 0.89 | MAPK14 (0.53) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL14989457 | 0.89 | MAPK14 (0.55) | MAPK14MAPK11ROCK2MAPK12STRADA | |
| SCHEMBL14989780 | 0.88 | MAPK14 (0.45) | MAPK14MAPK11MAPK1MAPKAPK5 | |
| SCHEMBL14990060 | 0.88 | MAPK14 (0.55) | MAPK14MAPK11ROCK2MAPK12STRADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056110-B2 | Substituted pyrimidinone-phenyl-pyrimidinyl compounds | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056110-B2 | Substituted pyrimidinone-phenyl-pyrimidinyl compounds | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056110-B2 | Substituted pyrimidinone-phenyl-pyrimidinyl compounds | CONFLUENCE LIFE SCIENCES, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| WO-2013086208-A1 | SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013086208-A1 | SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-20130143906-A1 | SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143906-A1 | SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-20130143906-A1 | SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS | CONFLUENCE LIFE SCIENCES, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-7183287-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040242608-A1 | Substituted pyrimidinones | PHARMACIA LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143906-A1 | SUBSTITUTED PYRIMIDINONE-PHENYL-PYRIMIDINYL COMPOUNDS | MAP3K8, MAP3K1, MAP3K2 | MAPK14 56/4885MAPK11 97/4885ROCK2 739/4885 |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885MAPK11 43/4885ROCK2 443/4885 |
| US-20040242608-A1 | Substituted pyrimidinones | MAPK1, MAPK7, MAP3K8 | MAPK14 29/4885MAPK11 48/4885ROCK2 409/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MAPK14 38/4885MAPK11 43/4885ROCK2 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.